Subtype
Liver Carcinoma
CI-CAN-00001073Explore in graph →
783 active trials14 approved drugs17 evidence items
- NCIt
- C7927
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001073Explore in graph →
Clinical trials
3,367 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (386)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02082210 | A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer | completed | Phase 1 / Phase 2 | 97 | Eli Lilly and CompanyINDUSTRY | 1 | Dec 19, 2020 | clinicaltrials |
| NCT02988440 | Study of Safety and Tolerability of PDR001 in Combination With Sorafenib and to Identify the Maximum Tolerated Dose and/or Phase 2 Dose for This Combination in Advanced Hepatocellular Patients | completed | Phase 1 | 20 | Novartis PharmaceuticalsINDUSTRY | 8 | Dec 19, 2020 |
| clinicaltrials |
| NCT01264705 | Study of Bavituximab and Sorafenib In Patients With Advanced Liver Cancer | completed | Phase 1 / Phase 2 | 47 | University of Texas Southwestern Medical CenterOTHER | 1 | Nov 12, 2020 | clinicaltrials |
| NCT03538028 | A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies | completed | Phase 1 | 22 | Incyte Biosciences International SàrlINDUSTRY | 1 | Oct 30, 2020 | clinicaltrials |
| NCT01835223 | Tivozanib in Treating Patients With Liver Cancer That Is Metastatic or Cannot Be Removed by Surgery | completed | Phase 1 / Phase 2 | 33 | Roswell Park Cancer InstituteOTHER | 1 | Oct 28, 2020 | clinicaltrials |
| NCT01938729 | Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Gemcitabine as Adjuvant Treatment After Resection of Intrahepatic Cholangiocarcinoma | completed | Phase 1 | 8 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 11, 2020 | clinicaltrials |
| NCT03289533 | A Study Of Avelumab In Combination With Axitinib In Advanced HCC (VEGF Liver 100) | completed | Phase 1 | 22 | PfizerINDUSTRY | 1 | Sep 4, 2020 | clinicaltrials |
| NCT02069145 | Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular Cancer | completed | Phase 1 | 10 | OncoMed Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 11, 2020 | clinicaltrials |
| NCT01099631 | IL-2 Expressing, Attenuated Salmonella Typhimurium in Unresectable Hepatic Spread | completed | Phase 1 | 22 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jul 20, 2020 | clinicaltrials |
| NCT02560779 | Trial of TRC105 and Sorafenib in Patients With HCC | completed | Phase 1 / Phase 2 | 27 | Tracon Pharmaceuticals Inc.INDUSTRY | 1 | Jul 17, 2020 | clinicaltrials |
| NCT02240433 | A Study of LY2157299 in Participants With Unresectable Hepatocellular Cancer (HCC) | completed | Phase 1 | 9 | Eli Lilly and CompanyINDUSTRY | 1 | Feb 5, 2020 | clinicaltrials |
| NCT03203005 | IMA970A Plus CV8102 in Very Early, Early and Intermediate Stage Hepatocellular Carcinoma Patients | completed | Phase 1 / Phase 2 | 22 | National Cancer Institute, NaplesOTHER | 5 | Feb 5, 2020 | clinicaltrials |
| NCT01853618 | Tremelimumab With Chemoembolization or Ablation for Liver Cancer | completed | Phase 1 / Phase 2 | 61 | National Cancer Institute (NCI)NIH | 1 | Dec 10, 2019 | clinicaltrials |
| NCT02387307 | A Study of rSIFN-co in Subjects With Advanced Solid Tumors(rSIFN-01) | completed | Phase 1 | 42 | Sichuan Huiyang Life Science and Technology CorporationINDUSTRY | 1 | Sep 27, 2019 | clinicaltrials |
| NCT02814461 | The Safety and Maximum Tolerated Dose of Axitinib in Combination With Radiotherapy for HCC | completed | Phase 1 | 9 | Shin Kong Wu Ho-Su Memorial HospitalOTHER | 1 | Sep 23, 2019 | clinicaltrials |
| NCT03008343 | Combination of Irreversible Electroporation and NK Immunotherapy for Recurrent Liver Cancer | completed | Phase 1 / Phase 2 | 20 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 12, 2019 | clinicaltrials |
| NCT02395250 | Anti-GPC3 CAR T for Treating Patients With Advanced HCC | completed | Phase 1 | 13 | RenJi HospitalOTHER | 1 | Aug 28, 2019 | clinicaltrials |
| NCT01008917 | Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma | completed | Phase 1 | 25 | University of California, San FranciscoOTHER | 1 | May 9, 2019 | clinicaltrials |
| NCT02151864 | LDE225 in Patients With Advanced or Metastatic Hepatocellular Carcinoma and Child-Pugh A/B7 Cirrhosis | completed | Phase 1 | 9 | Jason K. Sicklick, M.D.OTHER | 1 | Mar 5, 2019 | clinicaltrials |
| NCT00441376 | A Study of ThermoDox™ in Combination With Radiofrequency Ablation (RFA) in Primary and Metastatic Tumors of the Liver | completed | Phase 1 | 30 | ImunonINDUSTRY | 1 | Feb 7, 2019 | clinicaltrials |
| NCT00946153 | Study of Lenvatinib (E7080) in Participants With Advanced Hepatocellular Carcinoma (HCC) | completed | Phase 1 / Phase 2 | 66 | Eisai Co., Ltd.INDUSTRY | 2 | Feb 1, 2019 | clinicaltrials |
| NCT01306058 | Sorafenib and TRC105 in Hepatocellular Cancer | completed | Phase 1 / Phase 2 | 27 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2019 | clinicaltrials |
| NCT02191878 | Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Intravenous TKM-080301 in Subjects With Advanced Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 43 | Arbutus Biopharma CorporationINDUSTRY | 6 | Jan 16, 2019 | clinicaltrials |
| NCT01258608 | Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 101 | Human Genome Sciences Inc., a GSK CompanyINDUSTRY | 7 | Dec 19, 2018 | clinicaltrials |
| NCT02069041 | A Study of Ramucirumab (LY3009806) in Participants With Advanced Liver Cancer | completed | Phase 1 | 8 | Eli Lilly and CompanyINDUSTRY | 1 | Nov 21, 2018 | clinicaltrials |
| NCT02960594 | hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse(TRT-001) | completed | Phase 1 | 93 | Inovio PharmaceuticalsINDUSTRY | 1 | Nov 19, 2018 | clinicaltrials |
| NCT03515252 | Study of Autologous Immune Killer Cells in Patients With Late Stage Hepatocellular Carcinoma or Lung Cancer | completed | Phase 1 | 20 | Ivy Life Sciences, Co., LtdINDUSTRY | 0 | May 9, 2018 | clinicaltrials |
| NCT01665937 | STA-9090 in Patients With Advanced Hepatocellular Cancer | completed | Phase 1 | 16 | Massachusetts General HospitalOTHER | 1 | Apr 25, 2018 | clinicaltrials |
| NCT02400788 | Resminostat (YHI-1001) in Combination With Sorafenib in Asian Patients With Advanced Hepatocellular Carcinoma (HCC) | completed | Phase 1 / Phase 2 | 179 | Yakult Honsha Co., LTDINDUSTRY | 2 | Jan 16, 2018 | clinicaltrials |
| NCT00526617 | A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients | completed | Phase 1 | 41 | AbbVieINDUSTRY | 0 | Nov 21, 2017 | clinicaltrials |
| NCT00370513 | A Phase I Study of Pazopanib in Adult Patients With Liver Cancer | completed | Phase 1 | 28 | GlaxoSmithKlineINDUSTRY | 3 | Nov 17, 2017 | clinicaltrials |
| NCT00321594 | Belinostat in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery | completed | Phase 1 / Phase 2 | 54 | National Cancer Institute (NCI)NIH | 2 | Nov 6, 2017 | clinicaltrials |
| NCT01974661 | Phase I Safety Study of Dendritic Cell Vaccine to Treat Patients With Hepatocellular Carcinoma | completed | Phase 1 | 18 | MendusINDUSTRY | 1 | Sep 29, 2017 | clinicaltrials |
| NCT00706576 | Treatment of Unresectable Hepatocellular Cancer With Opioid Growth Factor | completed | Phase 1 | 14 | University of Missouri-ColumbiaOTHER | 1 | Aug 2, 2017 | clinicaltrials |
| NCT00920192 | Safety Study of Foretinib (GSK1363089) in Adults With Liver Cancer | completed | Phase 1 | 45 | GlaxoSmithKlineINDUSTRY | 3 | Jul 18, 2017 | clinicaltrials |
| NCT00861783 | Safety of ON 01910.Na and Irinotecan or ON 01910.Na and Oxaliplatin in Patients With Hepatoma | completed | Phase 1 | 16 | Traws Pharma, Inc.INDUSTRY | 1 | Jun 23, 2017 | clinicaltrials |
| NCT01839604 | A Phase I/Ib Study of AZD9150 (ISIS-STAT3Rx) in Patients With Advanced/Metastatic Hepatocellular Carcinoma | completed | Phase 1 | 58 | AstraZenecaINDUSTRY | 4 | Mar 6, 2017 | clinicaltrials |
| NCT01656265 | Study of ARQ 197 in Hepatocellular Carcinoma (HCC) | completed | Phase 1 | 24 | Kyowa Kirin Co., Ltd.INDUSTRY | 1 | Mar 3, 2017 | clinicaltrials |
| NCT01668134 | Stereotactic Body Radiotherapy for Hepatocellular Carcinoma, and Intrahepatic Cholangiocarcinoma | completed | Phase 1 | 28 | Washington University School of MedicineOTHER | 1 | Feb 20, 2017 | clinicaltrials |
| NCT00516165 | RAD001 in Advanced Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 28 | Massachusetts General HospitalOTHER | 1 | Feb 7, 2017 | clinicaltrials |
| NCT01308723 | A Dose-Finding and Exploratory Study of RO5323441 in Combination With Sorafenib in Patients With Hepatocellular Carcinoma | completed | Phase 1 | 6 | Hoffmann-La RocheINDUSTRY | 1 | Nov 2, 2016 | clinicaltrials |
| NCT01897038 | A Safety, Tolerability, and Pharmacokinetics Study of Onartuzumab as Single Agent or in Combination With Sorafenib in Participants With Advanced Hepatocellular Carcinoma | completed | Phase 1 | 9 | Hoffmann-La RocheINDUSTRY | 4 | Nov 2, 2016 | clinicaltrials |
| NCT01522820 | Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors | completed | Phase 1 | 18 | Roswell Park Cancer InstituteOTHER | 1 | Oct 4, 2016 | clinicaltrials |
| NCT00846131 | Y-90 Alone or With Sorafenib for Pre-Transplant Hepatocellular Carcinoma | completed | Phase 1 | 24 | Northwestern UniversityOTHER | 1 | Sep 15, 2016 | clinicaltrials |
| NCT01733004 | A Phase 1 Study of MM-141 in Patients With Advanced Solid Tumors | completed | Phase 1 | 42 | Merrimack PharmaceuticalsINDUSTRY | 2 | Aug 4, 2016 | clinicaltrials |
| NCT01008566 | Cixutumumab and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer | completed | Phase 1 | 21 | National Cancer Institute (NCI)NIH | 1 | May 12, 2016 | clinicaltrials |
| NCT00826384 | Transarterial Chemoembolization (TACE) Therapy of Hepatocellular Carcinoma (HCC) With Blocking Tumor Blood Temporarily and Enhancing Perfusion | completed | Phase 1 / Phase 2 | 352 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Apr 1, 2016 | clinicaltrials |
| NCT02724332 | Adjuvant Anti-Recurrence Treatment With Rapamycin on Early-stage HCC | completed | Phase 1 | 300 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Mar 31, 2016 | clinicaltrials |
Data updated 22 days agoSource updated Dec 19, 2020source: clinicaltrials